

### AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. **(Previously Presented)** An isolated nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding a mammalian transcription factor comprising an amino acid sequence having at least 75% identity to SEQ ID NO:8 (human SOM) or SEQ ID NO:16 (murine SOM) after optimal alignment.

2. **(Previously Presented)** The isolated nucleic acid molecule of claim 1 wherein the molecule has a nucleotide sequence selected from the group consisting of: SEQ ID NO: 7 (human *som*), SEQ ID NO: 15 (murine *som*), and a nucleotide sequence capable of hybridizing to SEQ ID NO: 7, SEQ ID NO:15 or a complementary form of any of the foregoing under high stringency conditions (0.1X SSC, 0.1% w/v SDS at 65°C).

3. **(Previously Presented)** The isolated nucleic acid molecule of claim 1 encoding a polypeptide comprising an amino acid sequence selected from SEQ ID NO: 8 or SEQ ID NO: 16.

4. **(Original)** The isolated nucleic acid molecule of claim 1 comprising a nucleotide sequence selected from SEQ ID NO: 7 and SEQ ID NO: 15.

5. **(Previously Presented)** The isolated nucleic acid molecule of Claim 1 comprising the nucleotide sequence set forth in SEQ ID NO: 7.

6. **(Previously Presented)** The isolated nucleic acid molecule of Claim 1 comprising the nucleotide sequence set forth in SEQ ID NO: 15.

7. **(Currently Amended, Withdrawn)** A pharmaceutical composition for the treatment of a genetic or physiological disorder, comprising:

an isolated nucleic acid molecule according to Claim 1 ~~comprising a sequence of nucleotides encoding or complementary to a sequence encoding a mammalian homolog of *Drosophila grh* wherein the nucleic acid molecule encodes a transcription factor selected from the group consisting of: human SEQ ID NO: 2 (MGR p49), SEQ ID NO: 4 (human MGR p70), SEQ ID NO: 6 (human BOM), SEQ ID NO: 7 (human SOM), SEQ ID NO: 10 (murine MGR p61), SEQ ID NO: 12 (murine MGR p70), SEQ ID NO: 14 (murine BOM) and SEQ ID NO: 16) murine SOM), a transcription factor having at least 65% identity to SEQ ID NO: 2, a transcription factor having at least 65% identity to SEQ ID NO: 4, a transcription factor having at least 65% identity to SEQ ID NO: 6, a transcription factor having at least 65% identity to SEQ ID~~

~~NO: 7, a transcription factor having at least 65% identity to SEQ ID NO: 10, a transcription factor having at least 65% identity to SEQ ID NO: 12, a transcription factor having at least 65% identity to SEQ ID NO: 14, and a transcription factor having at least 65% identity to SEQ ID NO: 16 after optimal alignment in an amount effective to treat said genetic or physiological disorder.~~

8-11. (Canceled)

12. (Currently Amended, Withdrawn) A method for treating spinabifida or other physiological or genetic disorders in a patient, comprising

administering to said patient an isolated nucleic acid molecule according to Claim 1 ~~mammalian transcription factor which is a homolog of *Drosophila* grainyhead (GRH) selected from the group consisting of: human SEQ ID NO: 2 (MGR p49), SEQ ID NO: 4 (human MGR p70), SEQ ID NO: 6 (human BOM), SEQ ID NO: 8 (human SOM), SEQ ID NO: 10 (murine MGR p61), SEQ ID NO: 12 (murine MGR p70), SEQ ID NO: 14 (murine BOM) and SEQ ID NO: 16 (murine SOM) and~~, a molecule having at least 75% identity to ~~SEQ ID NO: 2, a molecule having at least 75% identity to SEQ ID NO: 4, a molecule having at least 75% identity to SEQ ID NO: 6, a molecule having at least 75% identity to SEQ ID NO: 8, a molecule having at least 75% identity to SEQ ID NO: 10, a molecule having at least 75% identity to SEQ ID NO: 12, a molecule having at least 75% identity to SEQ ID NO: 14, and a molecule having at least 75% identity to SEQ ID NO: 16 after optimal alignment in an amount effective for the treatment of spinabifida or other physiological or genetic disorder.~~

13-15. (Canceled)

16. (Currently Amended, Withdrawn) The method of Claim 12 ~~pharmaceutical composition of Claim 7, wherein said genetic disorder~~ method is for treating spinabifida.

17-21. (Canceled)